Gilead Sciences (NASDAQ:GILD) CFO Andrew Dickinson Sells 2,500 Shares of Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew Dickinson sold 2,500 shares of the firm’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the sale, the chief financial officer directly owned 157,055 shares of the company’s stock, valued at $18,545,054.40. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Gilead Sciences Stock Up 4.2%

GILD stock opened at $122.81 on Friday. Gilead Sciences, Inc. has a one year low of $85.60 and a one year high of $124.11. The firm has a market cap of $152.38 billion, a PE ratio of 24.46, a PEG ratio of 0.81 and a beta of 0.34. The firm’s 50 day moving average price is $115.22 and its 200-day moving average price is $110.53. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same quarter last year, the firm posted $2.01 earnings per share. Gilead Sciences’s revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s dividend payout ratio is presently 62.95%.

Institutional Investors Weigh In On Gilead Sciences

Several hedge funds have recently modified their holdings of GILD. Vanguard Group Inc. raised its position in Gilead Sciences by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after buying an additional 1,893,401 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Gilead Sciences by 2.6% during the second quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock worth $3,231,548,000 after acquiring an additional 727,515 shares during the period. Norges Bank purchased a new position in Gilead Sciences during the second quarter worth about $2,150,268,000. Price T Rowe Associates Inc. MD raised its holdings in Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after purchasing an additional 11,156,382 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Gilead Sciences by 12.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock valued at $1,541,302,000 after purchasing an additional 1,520,809 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have issued reports on the company. UBS Group lifted their price target on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a report on Friday, August 8th. Cantor Fitzgerald boosted their target price on Gilead Sciences from $129.00 to $135.00 and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Rothschild & Co Redburn upped their price target on Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a report on Friday, September 12th. Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Finally, Royal Bank Of Canada boosted their price objective on shares of Gilead Sciences from $98.00 to $100.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.65.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.